Defence Therapeutics expands radiopharmaceutical strategy to test alpha and beta emitters

PUBT · 2d ago
Defence Therapeutics expands radiopharmaceutical strategy to test alpha and beta emitters
  • Defence Therapeutics expanded its radiopharmaceutical strategy to run parallel alpha- and beta-emitter development programs for Accum-enabled candidates.
  • Planned work targets comparative pharmacology, efficacy, safety data to guide isotope selection and accelerate clinical-candidate nomination.
  • Program will test Actinium-225-class alpha emitters versus Lutetium-177-class beta emitters to match payload profiles with intracellular delivery performance.
  • Preclinical efforts aim to increase tumor-cell accumulation while reducing off-target toxicity, supporting a broader proprietary radiopharmaceutical pipeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Defence Therapeutics Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608310315NEWSFILECNPR____20260831_311969_1) on August 31, 2026, and is solely responsible for the information contained therein.